journal
MENU ▼
Read by QxMD icon Read
search

Lancet Diabetes & Endocrinology

journal
https://www.readbyqxmd.com/read/28733172/sgtl2-inhibitors-and-amputations-in-the-us-fda-adverse-event-reporting-system
#1
LETTER
Gian Paolo Fadini, Angelo Avogaro
No abstract text is available yet for this article.
July 18, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28716631/measures-of-chronic-kidney-disease-and-risk-of-incident-peripheral-artery-disease-a-collaborative-meta-analysis-of-individual-participant-data
#2
Kunihiro Matsushita, Shoshana H Ballew, Josef Coresh, Hisatomi Arima, Johan Ärnlöv, Massimo Cirillo, Natalie Ebert, Jade S Hiramoto, Heejin Kimm, Michael G Shlipak, Frank L J Visseren, Ron T Gansevoort, Csaba P Kovesdy, Varda Shalev, Mark Woodward, Florian Kronenberg
BACKGROUND: Some evidence suggests that chronic kidney disease is a risk factor for lower-extremity peripheral artery disease. We aimed to quantify the independent and joint associations of two measures of chronic kidney disease (estimated glomerular filtration rate [eGFR] and albuminuria) with the incidence of peripheral artery disease. METHODS: In this collaborative meta-analysis of international cohorts included in the Chronic Kidney Disease Prognosis Consortium (baseline measurements obtained between 1972 and 2014) with baseline measurements of eGFR and albuminuria, at least 1000 participants (this criterion not applied to cohorts exclusively enrolling patients with chronic kidney disease), and at least 50 peripheral artery disease events, we analysed adult participants without peripheral artery disease at baseline at the individual patient level with Cox proportional hazards models to quantify associations of creatinine-based eGFR, urine albumin-to-creatinine ratio (ACR), and dipstick proteinuria with the incidence of peripheral artery disease (including hospitalisation with a diagnosis of peripheral artery disease, intermittent claudication, leg revascularisation, and leg amputation)...
July 14, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28716630/common-measures-of-chronic-kidney-disease-improve-vascular-risk-prediction
#3
Austin G Stack
No abstract text is available yet for this article.
July 14, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28711471/sensor-mightier-than-pump-the-jury-is-still-out
#4
Roman Hovorka
No abstract text is available yet for this article.
July 12, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28711470/looking-again-at-the-look-ahead-study
#5
Edward W Gregg, Rena Wing
No abstract text is available yet for this article.
July 12, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28711469/targeting-weight-loss-interventions-to-reduce-cardiovascular-complications-of-type-2-diabetes-a-machine-learning-based-post-hoc-analysis-of-heterogeneous-treatment-effects-in-the-look-ahead-trial
#6
Aaron Baum, Joseph Scarpa, Emilie Bruzelius, Ronald Tamler, Sanjay Basu, James Faghmous
BACKGROUND: The Action for Health in Diabetes (Look AHEAD) trial investigated whether long-term cardiovascular disease morbidity and mortality could be reduced through a weight loss intervention among people with type 2 diabetes. Despite finding no significant reduction in cardiovascular events on average, it is possible that some subpopulations might have derived benefit. In this post-hoc analysis, we test the hypothesis that the overall neutral average treatment effect in the trial masked important heterogeneous treatment effects (HTEs) from intensive weight loss interventions...
July 12, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28711468/effect-of-initiating-use-of-an-insulin-pump-in-adults-with-type-1-diabetes-using-multiple-daily-insulin-injections-and-continuous-glucose-monitoring-diamond-a-multicentre-randomised-controlled-trial
#7
Roy W Beck, Tonya D Riddlesworth, Katrina J Ruedy, Craig Kollman, Andrew J Ahmann, Richard M Bergenstal, Anuj Bhargava, Bruce W Bode, Stacie Haller, Davida F Kruger, Janet B McGill, William Polonsky, David Price, Elena Toschi
BACKGROUND: The benefit of initiation of insulin pump therapy (continuous subcutaneous insulin infusion; CSII) in patients with type 1 diabetes using continuous glucose monitoring (CGM) has not been studied. We aimed to assess glycaemic outcomes when switching from multiple daily injections (MDI) to CSII in adults with type 1 diabetes using CGM. METHODS: In this multicentre, randomised controlled trial, 75 adults with type 1 diabetes in the CGM group of the DIAMOND trial were randomly assigned via the study website using a computer-generated sequence to continue MDI or switch to CSII, with continuation of CGM, for 28 weeks...
July 12, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28689769/osteoporosis-treatment-recent-developments-and-ongoing-challenges
#8
REVIEW
Sundeep Khosla, Lorenz C Hofbauer
Osteoporosis is an enormous and growing public health problem. Once considered an inevitable consequence of ageing, it is now eminently preventable and treatable. Ironically, despite tremendous therapeutic advances, there is an increasing treatment gap for patients at high fracture risk. In this Series paper, we trace the evolution of drug therapy for osteoporosis, which began in the 1940s with the demonstration by Fuller Albright that treatment with oestrogen could reverse the negative calcium balance that developed in women after menopause or oophorectomy...
July 6, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28689768/use-of-bone-turnover-markers-in-postmenopausal-osteoporosis
#9
REVIEW
Richard Eastell, Pawel Szulc
Bone turnover comprises two processes: the removal of old bone (resorption) and the laying down of new bone (formation). N-terminal propeptide of type I procollagen (PINP) and C-telopeptide of type I collagen (CTX-I) are markers of bone formation and resorption, respectively, that are recommended for clinical use. Bone turnover markers can be measured on several occasions in one individual with good precision. However, these markers are subject to several sources of variability, including feeding (resorption decreases) and recent fracture (all markers increase for several months)...
July 6, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28688820/the-crisis-of-diabetes-in-sub-saharan-africa
#10
Shabbar Jaffar, Geoffrey Gill
No abstract text is available yet for this article.
July 5, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28688819/diabetes-in-sub-saharan-africa-let-us-not-forget-type-1
#11
Silver K Bahendeka
No abstract text is available yet for this article.
July 5, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28688818/diabetes-in-sub-saharan-africa-from-clinical-care-to-health-policy
#12
REVIEW
Rifat Atun, Justine I Davies, Edwin A M Gale, Till Bärnighausen, David Beran, Andre Pascal Kengne, Naomi S Levitt, Florence W Mangugu, Moffat J Nyirenda, Graham D Ogle, Kaushik Ramaiya, Nelson K Sewankambo, Eugene Sobngwi, Solomon Tesfaye, John S Yudkin, Sanjay Basu, Christian Bommer, Esther Heesemann, Jennifer Manne-Goehler, Iryna Postolovska, Vera Sagalova, Sebastian Vollmer, Zulfiqarali G Abbas, Benjamin Ammon, Mulugeta Terekegn Angamo, Akhila Annamreddi, Ananya Awasthi, Stéphane Besançon, Sudhamayi Bhadriraju, Agnes Binagwaho, Philip I Burgess, Matthew J Burton, Jeanne Chai, Felix P Chilunga, Portia Chipendo, Anna Conn, Dipesalema R Joel, Arielle W Eagan, Crispin Gishoma, Julius Ho, Simcha Jong, Sujay S Kakarmath, Yasmin Khan, Ramu Kharel, Michael A Kyle, Seitetz C Lee, Amos Lichtman, Carl P Malm, Maïmouna N Mbaye, Marie A Muhimpundu, Beatrice M Mwagomba, Kibachio Joseph Mwangi, Mohit Nair, Simon P Niyonsenga, Benson Njuguna, Obiageli L O Okafor, Oluwakemi Okunade, Paul H Park, Sonak D Pastakia, Chelsea Pekny, Ahmed Reja, Charles N Rotimi, Samuel Rwunganira, David Sando, Gabriela Sarriera, Anshuman Sharma, Assa Sidibe, Elias S Siraj, Azhra S Syed, Kristien Van Acker, Mahmoud Werfalli
No abstract text is available yet for this article.
July 5, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28666776/sglt2-inhibition-a-new-era-in-renoprotective-medicine
#13
Marcel H A Muskiet, Hiddo J L Heerspink, Daniël H van Raalte
No abstract text is available yet for this article.
June 27, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28666775/effects-of-empagliflozin-on-the-urinary-albumin-to-creatinine-ratio-in-patients-with-type-2-diabetes-and-established-cardiovascular-disease-an-exploratory-analysis-from-the-empa-reg-outcome-randomised-placebo-controlled-trial
#14
David Z I Cherney, Bernard Zinman, Silvio E Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, Maximilian von Eynatten, Christoph Wanner
BACKGROUND: In a pooled analysis of short-term trials, short-term treatment with the sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin reduced albuminuria in patients with type 2 diabetes and prevalent albuminuria. In this exploratory analysis of the EMPA-REG OUTCOME trial, we report the short-term and long-term effects of empagliflozin on albuminuria in patients with type 2 diabetes and established cardiovascular disease, according to patients' baseline albuminuria status...
June 27, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28629907/the-role-of-biosimilar-manufacturers-in-improving-access-to-insulin-globally
#15
LETTER
Christophe Perrin, Margaret Ewen, David Beran
No abstract text is available yet for this article.
June 16, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28615150/metformin-in-type-1-diabetes
#16
Eberhard Standl
No abstract text is available yet for this article.
June 9, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28615149/cardiovascular-and-metabolic-effects-of-metformin-in-patients-with-type-1-diabetes-removal-a-double-blind-randomised-placebo-controlled-trial
#17
John R Petrie, Nishi Chaturvedi, Ian Ford, Martijn C G J Brouwers, Nicola Greenlaw, Therese Tillin, Irene Hramiak, Alun D Hughes, Alicia J Jenkins, Barbara E K Klein, Ronald Klein, Teik C Ooi, Peter Rossing, Coen D A Stehouwer, Naveed Sattar, Helen M Colhoun
BACKGROUND: Metformin might reduce insulin requirement and improve glycaemia in patients with type 1 diabetes, but whether it has cardiovascular benefits is unknown. We aimed to investigate whether metformin treatment (added to titrated insulin therapy) reduced atherosclerosis, as measured by progression of common carotid artery intima-media thickness (cIMT), in adults with type 1 diabetes at increased risk for cardiovascular disease. METHODS: REMOVAL was a double-blind, placebo-controlled trial undertaken at 23 hospital diabetes clinics in five countries (Australia, Canada, Denmark, the Netherlands, and the UK)...
June 9, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28606729/person-centred-type-2-diabetes-care-time-for-a-paradigm-shift
#18
Guy E H M Rutten, Aus Alzaid
No abstract text is available yet for this article.
June 9, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28602362/correction-to-lancet-diabetes-endocrinol-2017-published-online-june-7-http-dx-doi-org-10-1016-s2213-8587-17-30174-2
#19
(no author information available yet)
No abstract text is available yet for this article.
June 8, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28601585/prevalence-of-diabetes-and-prediabetes-in-15-states-of-india-results-from-the-icmr-indiab-population-based-cross-sectional-study
#20
Ranjit Mohan Anjana, Mohan Deepa, Rajendra Pradeepa, Jagadish Mahanta, Kanwar Narain, Hiranya Kumar Das, Prabha Adhikari, Paturi Vishnupriya Rao, Banshi Saboo, Ajay Kumar, Anil Bhansali, Mary John, Rosang Luaia, Taranga Reang, Somorjit Ningombam, Lobsang Jampa, Richard O Budnah, Nirmal Elangovan, Radhakrishnan Subashini, Ulagamathesan Venkatesan, Ranjit Unnikrishnan, Ashok Kumar Das, Sri Venkata Madhu, Mohammed K Ali, Arvind Pandey, Rupinder Singh Dhaliwal, Tanvir Kaur, Soumya Swaminathan, Viswanathan Mohan
BACKGROUND: Previous studies have not adequately captured the heterogeneous nature of the diabetes epidemic in India. The aim of the ongoing national Indian Council of Medical Research-INdia DIABetes study is to estimate the national prevalence of diabetes and prediabetes in India by estimating the prevalence by state. METHODS: We used a stratified multistage design to obtain a community-based sample of 57 117 individuals aged 20 years or older. The sample population represented 14 of India's 28 states (eight from the mainland and six from the northeast of the country) and one union territory...
June 7, 2017: Lancet Diabetes & Endocrinology
journal
journal
47944
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"